My understanding of dosing with empagliflozin, in particular, is that it is not dose-dependent, thus a dose of 10 mg versus 25 mg will lead to a similar reduction in proteinuria. This is based on data from the EMPA REG OUTCOME trial published in NEJM in 2016. The composite outcome of incident or wor...

I far as I am aware this has not been studied yet. My belief is that if the amount of glucosuria and sodium excretion increases with higher doses, then higher doses would be more effective. It is also possible that even the lower doses already cause maximum inhibition of SGLT-2 and further increases...